argenx

argenx is a global, commercial-stage biopharmaceutical company focused on developing and commercializing innovative antibody-based therapies for severe autoimmune diseases and cancer, leveraging its proprietary antibody engineering platform and collaborations with leading academic researchers. The company’s lead product, efgartigimod, is the first approved FcRn blocker in multiple major markets, and argenx is advancing a deep pipeline of experimental medicines, positioning itself as a leader in next-generation immunology therapeutics.

Company Facts

• Headquarters: Amsterdam, Netherlands
• Founded: 2008
• Employees: 1,148
• Type: Public Corporation (Societas Europaea)
• Website: https://www.argenx.com
• Industries: Biotechnology, Pharmaceuticals, Immunology, Healthcare, Life Sciences